Search Results 81-90 of 290 for ⚕코인카지노 【위너보증.com / 가입코드 9122】 샬롬가입코드.샬롬주소 ⚕

  1. CSF1R and TAM receptor inhibition with Q702 - Mayo Clinic

    The purpose of this study is establish the highest dose of Q702 tested that has acceptable tolerability and safety. Participation eligibility. Participant ...

  2. A Study to Determine the Effectiveness and Safety of Benralizumab for Patients with Severe Nasal Polyposis - Mayo Clinic

    The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with severe bilateral nasal polyposis who are still ...

  3. An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738) - Mayo Clinic

    The purpose of Part I of the study is to assess the efficacy and safety of MK-8931 compared with placebo administered for 78 weeks in the treatment of ...

  4. A Study to Evaluate the Effectiveness and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis (SPIRIT) - Mayo Clinic

    The primary purpose of this study is to evaluate the effectiveness of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).

  5. Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

    This is a multicenter, international, double-blind study of the administration of mavacamten in participants with symptomatic obstructive HCM (oHCM).

  6. A Study to Evaluate Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) to Treat Acute Myelogenous Leukemia (AML) Patients - Mayo Clinic

    The purpose of this study is to determine a recommended phase 2 dose (RP2D) of pevonedistat, azacitidine (or decitabine), and venetoclax to treat Acute ...

  7. A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib - Mayo Clinic

    Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 ...

  8. A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  9. Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA - Mayo Clinic

    Will rigosertib, with an aggressive infusion dose, improve overall survival of MDS better than the treatments available today? Participation eligibility.

  10. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify ...